GlassScriptPhysician profile
Elyiahu Rubin
NPI 1619967502
$4,471.86
in general payments reported to CMS, 2019-2025
26 companies · $788 in 2025
The $788 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,204 · 2020: $96.74 · 2022: $711 · 2023: $470 · 2024: $1,203 · 2025: $788.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,461.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,460.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Chiesi USA, INC. | $478.31 | 2024-2025 | Mycapssa, Myalept |
| Abbott Laboratories | $470.44 | 2019-2025 | Cardiomems, Freestyle Libre 3 |
| Corcept Therapeutics | $264.61 | 2019-2022 | |
| Esperion Therapeutics, INC. | $232.73 | 2022-2024 | Nexletol |
| Otsuka America Pharmaceutical, INC. | $226.65 | 2019 | |
| Recordati_rare_diseases_inc. | $217.89 | 2024-2025 | Isturisa |
| Sanofi-Aventis U.S. LLC | $211.32 | 2020-2024 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $193.92 | 2019-2023 | Lifevest |
| E.R. Squibb & Sons, L.L.C. | $192.10 | 2024 | Camzyos |
| Ascensia Diabetes Care US INC. | $165.50 | 2023 | |
| Medtronic, INC. | $160.53 | 2023-2024 | Minimed 780g |
| Neurocrine Biosciences, INC. | $138.35 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $129.49 | 2019-2023 | Jardiance |
| Kyowa Kirin, INC. | $128.38 | 2025 | |
| Alnylam Pharmaceuticals INC. | $121.81 | 2022 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $119.99 | 2022 | |
| Averitas Pharma INC. | $118.74 | 2025 | Qutenza |
| Amgen INC. | $117.92 | 2023 | Evenity |
| Abbvie INC. | $117.01 | 2019 | |
| Ipsen Biopharmaceuticals, INC | $116.81 | 2019 | |
| Novo Nordisk INC | $112.52 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $110.70 | 2019 | |
| Merck Sharp & Dohme LLC | $109.38 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $96.17 | 2019 | |
| Biomarin Pharmaceutical INC. | $95.13 | 2022 | |
| Bridgebio Pharma, INC. | $25.46 | 2025 | Attruby |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elyiahu Rubin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.